CDC Report Shows High Efficacy from mRNA COVID-19 Vaccines


In a 4000 person study, investigators find vaccinated individuals unlikely to transmit COVID-19.

This article was originally published in ContagionLive.

A new report from the US Centers for Disease Control and Prevention (CDC) highlights extensive efficacy in preventing infections from the Moderna and Pfizer-BioNTech COVID-19 vaccines.

The report shows the 2 vaccines were 90% effective in preventing infections—regardless of symptom status—14 days after the second dose was administered.

In addition, the 2 vaccines were 80% effective 14 days after the first dose, but before the second dose.

The findings come from studying nearly 4000 health care personnel, first responders, and other frontline workers from mid-December 2020 through mid-March 2021. The participants were tested weekly for 13 weeks in 8 US locations.

According to the CDC, both vaccines were given to participants in all the locations, but the timing on their availability differed. Of the vaccinated, 62.7% of participants received the Pfizer-BioNTech shot and 29.6% received the Moderna shot.

In addition, more data from these studies is showing that transmission is unlikely from people who have been vaccinated.

“Among fully immunized (≥14 days after second dose) persons, 0.04 infections per 1000 person-days were reported, and among partially immunized (≥14 days after first dose and before second dose) persons, 0.19 infections per 1000 person-days were reported,” the CDC stated on their website.

Obviously, this comes as optimistic news in light of some surging cases in various parts of the US and the concern of the B.1117 variant—first discovered in the United Kingdom—is becoming the dominant strain.

“These findings indicate that authorized mRNA COVID-19 vaccines are effective for preventing SARS-CoV-2 infection, regardless of symptom status, among working-age adults in real-world conditions,” the CDC stated.

Related Videos
Nanette B. Silverberg, MD: Uncovering Molluscum Epidemiology
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
A Year of RSV Highs and Lows, with Tina Tan, MD
Ryan A. Smith, MD: RSV Risk in Patients with IBD
Julia Moore Vogel, PhD, MBA: How Do We Define Long Covid Patients?
Julia Moore Vogel, PhD, MBA: Long Covid Care Lacks Urgency
Balancing COVID-19 Risk and Wellness in Patients with Rheumatic Diseases
Exploring Patient Experiences, Challenges of Rheumatic Disease Management During the Pandemic
Cedric Rutland, MD: Exploring Immunology's Role in Molecule Development
Cedric Rutland, MD: Mechanisms Behind Immunology, Cellular Communication
© 2024 MJH Life Sciences

All rights reserved.